JP2009511548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511548A5 JP2009511548A5 JP2008535039A JP2008535039A JP2009511548A5 JP 2009511548 A5 JP2009511548 A5 JP 2009511548A5 JP 2008535039 A JP2008535039 A JP 2008535039A JP 2008535039 A JP2008535039 A JP 2008535039A JP 2009511548 A5 JP2009511548 A5 JP 2009511548A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidine
- alkyl
- diamine
- amino
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 16
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000001475 halogen functional group Chemical group 0.000 claims 11
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- -1 cyano, amino Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- LJFYCHRMDUDZIK-UHFFFAOYSA-N 2-[benzyl-[4-[(4-chlorophenyl)methylamino]pyrimidin-2-yl]amino]ethanol Chemical compound N=1C=CC(NCC=2C=CC(Cl)=CC=2)=NC=1N(CCO)CC1=CC=CC=C1 LJFYCHRMDUDZIK-UHFFFAOYSA-N 0.000 claims 1
- HILXMIDQWAJIIF-UHFFFAOYSA-N 2-n,4-n-bis[(3,4-dichlorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC1=CC=NC(NCC=2C=C(Cl)C(Cl)=CC=2)=N1 HILXMIDQWAJIIF-UHFFFAOYSA-N 0.000 claims 1
- RCIGVDDQJQWZRJ-UHFFFAOYSA-N 2-n,4-n-bis[(3,4-difluorophenyl)methyl]-6-methylpyrimidine-2,4-diamine Chemical compound N=1C(NCC=2C=C(F)C(F)=CC=2)=NC(C)=CC=1NCC1=CC=C(F)C(F)=C1 RCIGVDDQJQWZRJ-UHFFFAOYSA-N 0.000 claims 1
- AXMPXZDLSQGJQM-UHFFFAOYSA-N 2-n,4-n-bis[(3,4-difluorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=C(F)C(F)=CC=C1CNC1=CC=NC(NCC=2C=C(F)C(F)=CC=2)=N1 AXMPXZDLSQGJQM-UHFFFAOYSA-N 0.000 claims 1
- DSNKJRLJVOQOQE-UHFFFAOYSA-N 2-n,4-n-bis[(4-chlorophenyl)methyl]-2-n,4-n-dimethylpyrimidine-2,4-diamine Chemical compound C=1C=NC(N(C)CC=2C=CC(Cl)=CC=2)=NC=1N(C)CC1=CC=C(Cl)C=C1 DSNKJRLJVOQOQE-UHFFFAOYSA-N 0.000 claims 1
- VOWAWQAFBAMUME-UHFFFAOYSA-N 2-n,4-n-bis[(4-chlorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=CC(Cl)=CC=C1CNC1=CC=NC(NCC=2C=CC(Cl)=CC=2)=N1 VOWAWQAFBAMUME-UHFFFAOYSA-N 0.000 claims 1
- BCHGUHQTMMIADQ-UHFFFAOYSA-N 2-n,4-n-bis[1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine Chemical compound C=1C=C(F)C=CC=1C(C)NC(N=1)=CC=NC=1NC(C)C1=CC=C(F)C=C1 BCHGUHQTMMIADQ-UHFFFAOYSA-N 0.000 claims 1
- UQGDTTREHLFRPB-UHFFFAOYSA-N 2-n,4-n-bis[[3-(trifluoromethyl)phenyl]methyl]pyrimidine-2,4-diamine Chemical compound FC(F)(F)C1=CC=CC(CNC=2N=C(NCC=3C=C(C=CC=3)C(F)(F)F)N=CC=2)=C1 UQGDTTREHLFRPB-UHFFFAOYSA-N 0.000 claims 1
- HVLRQUVZTRNFQB-UHFFFAOYSA-N 2-n,4-n-bis[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]pyrimidine-2,4-diamine Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1CNC1=CC=NC(NCC=2C=C(C(F)=CC=2)C(F)(F)F)=N1 HVLRQUVZTRNFQB-UHFFFAOYSA-N 0.000 claims 1
- FUWYGWYBVZCUGU-UHFFFAOYSA-N 2-n,4-n-dibenzyl-2-n,4-n-bis[2-(dimethylamino)ethyl]pyrimidine-2,4-diamine Chemical compound C=1C=NC(N(CCN(C)C)CC=2C=CC=CC=2)=NC=1N(CCN(C)C)CC1=CC=CC=C1 FUWYGWYBVZCUGU-UHFFFAOYSA-N 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 206010040981 Sleep attacks Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000028311 absence seizure Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- CSNFMBGHUOSBFU-UHFFFAOYSA-N pyrimidine-2,4,5-triamine Chemical class NC1=NC=C(N)C(N)=N1 CSNFMBGHUOSBFU-UHFFFAOYSA-N 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72650805P | 2005-10-14 | 2005-10-14 | |
| DKPA200501439 | 2005-10-14 | ||
| PCT/EP2006/067387 WO2007042571A1 (en) | 2005-10-14 | 2006-10-13 | Novel pyrimidine-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511548A JP2009511548A (ja) | 2009-03-19 |
| JP2009511548A5 true JP2009511548A5 (enExample) | 2009-10-08 |
Family
ID=37680620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535039A Abandoned JP2009511548A (ja) | 2005-10-14 | 2006-10-13 | 新規ピリミジン−２，４−ジアミン誘導体及び小コンダクタンスのカルシウム依存性カリウムチャネルのモジュレーターとしてのこれらの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20090124645A1 (enExample) |
| EP (1) | EP1940804A2 (enExample) |
| JP (1) | JP2009511548A (enExample) |
| WO (1) | WO2007042571A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2665398A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| JP2010111702A (ja) | 2009-02-16 | 2010-05-20 | Tetsuya Nishio | 複素環化合物、その製造法および用途 |
| JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
| EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
| EP2760843B1 (en) * | 2011-09-26 | 2016-03-02 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN188411B (enExample) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004043936A1 (ja) | 2002-11-14 | 2004-05-27 | Kyowa Hakko Kogyo Co., Ltd. | Ｐｌｋ阻害剤 |
| WO2005011758A2 (en) | 2003-07-25 | 2005-02-10 | Ciba Specialty Chemicals Holding Inc. | Use of substituted 2,4-bis (alkylamino) pyrimidines or -quinazolines as antimicrobials |
| US7642354B2 (en) * | 2004-04-13 | 2010-01-05 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| WO2006074991A1 (en) * | 2005-01-11 | 2006-07-20 | Neurosearch A/S | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
-
2006
- 2006-10-13 WO PCT/EP2006/067387 patent/WO2007042571A1/en not_active Ceased
- 2006-10-13 EP EP06807251A patent/EP1940804A2/en not_active Withdrawn
- 2006-10-13 US US12/083,433 patent/US20090124645A1/en not_active Abandoned
- 2006-10-13 JP JP2008535039A patent/JP2009511548A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526815A5 (enExample) | ||
| US7528260B2 (en) | Method for preparing N-phenylpyrazole-1-carboxamides | |
| AU2010339423C1 (en) | Therapeutic compounds and related methods of use | |
| JP5016583B2 (ja) | アミノピリミジン化合物製造の原料化合物とその製造方法 | |
| CN101970416B (zh) | 制备喹唑啉酮衍生物的方法 | |
| JP2009519995A5 (enExample) | ||
| US8580960B2 (en) | Process for synthesis of phenoxy diaminopyrimidine derivatives | |
| JP2020506899A5 (enExample) | ||
| EP1796673A2 (en) | Novel pyrimidine compounds, process for their preparation and compositions containing them | |
| JP5490100B2 (ja) | ５−（２−アミノ−ピリミジン−４−イル）−２−アリール−ｌＨ−ピロール−３−カルボキサミドの製造方法 | |
| JP2008543915A5 (enExample) | ||
| JP2007509043A5 (enExample) | ||
| JP2008534472A5 (enExample) | ||
| JP2009511548A5 (enExample) | ||
| CN102471287A (zh) | 2-氨基-5-三氟甲基嘧啶衍生物的区域选择性制备方法 | |
| JP2010502674A5 (enExample) | ||
| US20080255111A1 (en) | Tissue Factor Production Inhibitor | |
| US9598369B2 (en) | Process for the preparation of amides from hindered anilines containing a perhaloalkyl group | |
| JP2009518338A (ja) | バニロイドアンタゴニストとしての三置換キナゾリノン誘導体 | |
| JP2009542602A5 (enExample) | ||
| US20130079519A1 (en) | Regioselective preparation of substituted pyrimidines | |
| JP2009530352A5 (enExample) | ||
| JP2010509249A5 (enExample) | ||
| JP2009518359A5 (enExample) | ||
| US7741484B2 (en) | Process for synthesis of phenoxy diaminopyrimidine derivatives |